A description of Lassa Fever mortality during the 2019 outbreak in Nigeria

Mba, Sandra; Ukponu, Winifred; Adekanye, Usman; Saleh, Mohammad; Agogo, Emmanuel; Dan-Nwafor, Chioma; Amao, Lateefat Kikelomo; Oparah, O B; Olajide, L.; Oyegoke, A.; Mba, Nwando; Ilori, Elsie; Ihekweazu, Chikwe

doi:10.1016/j.ijid.2020.09.1074

Cited by 6 publications

(9 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In Nigeria, reports showed that a total of 1615 LF cases were confirmed in 2021 [ 28 ]. Additionally, in 2019, 578 confirmed cases were reported in Nigeria [ 29 ].…”

Section: Epidemiology Of Lassa Fever In West African Countriesmentioning

confidence: 99%

“…As a result, early detection of infected patients is critical for the prompt implementation of carrier isolation nursing guidelines [ 26 ]. The virus infection is asymptomatic but persistent with high urinary viral excretion in Mastomys natalensis , the most common commensal rodent host [ 29 ]. Increased inter-border traffic and international travel have given rise to more virulent and contagious LASV in many communities in the endemic countries within the sub-region of West Africa and also increased the sporadic cases of the fever in non-endemic regions of Africa and other continents [ 33 ].…”

Section: Epidemiology Of Lassa Fever In West African Countriesmentioning

confidence: 99%

See 1 more Smart Citation

Combating Lassa Fever in West African Sub-Region: Progress, Challenges, and Future Perspectives

Aloke

Obasi

Aja

et al. 2023

Viruses

View full text Add to dashboard Cite

Lassa fever (LF) is a rodent-borne disease that threatens human health in the sub-region of West Africa where the zoonotic host of Lassa virus (LASV) is predominant. Currently, treatment options for LF are limited and since no preventive vaccine is approved for its infectivity, there is a high mortality rate in endemic areas. This narrative review explores the transmission, pathogenicity of LASV, advances, and challenges of different treatment options. Our findings indicate that genetic diversity among the different strains of LASV and their ability to circumvent the immune system poses a critical challenge to the development of LASV vaccines/therapeutics. Thus, understanding the biochemistry, physiology and genetic polymorphism of LASV, mechanism of evading host immunity are essential for development of effective LASV vaccines/therapeutics to combat this lethal viral disease. The LASV nucleoprotein (NP) is a novel target for therapeutics as it functions significantly in several aspects of the viral life cycle. Consequently, LASV NP inhibitors could be employed as effective therapeutics as they will potentially inhibit LASV replication. Effective preventive control measures, vaccine development, target validation, and repurposing of existing drugs, such as ribavirin, using activity or in silico-based and computational bioinformatics, would aid in the development of novel drugs for LF management.

show abstract

“…In Nigeria, reports showed that a total of 1615 LF cases were confirmed in 2021 [ 28 ]. Additionally, in 2019, 578 confirmed cases were reported in Nigeria [ 29 ].…”

Section: Epidemiology Of Lassa Fever In West African Countriesmentioning

confidence: 99%

Section: Epidemiology Of Lassa Fever In West African Countriesmentioning

confidence: 99%

Combating Lassa Fever in West African Sub-Region: Progress, Challenges, and Future Perspectives

Aloke

Obasi

Aja

et al. 2023

Viruses

View full text Add to dashboard Cite

show abstract

“…One abstract used a cross-sectional analysis of a national database in Nigeria to examine 578 cases of Lassa fever, with 31% with hypertension, but again, no formal statistical comparison between groups was performed. 42…”

Section: Viral Mortalitymentioning

confidence: 99%

“…There were surprisingly only 15 studies on other emerging viral infections (virus families arenaviridae, bunyaviridae, filoviridae, flaviviridae, togaviridae, poxviridae, paramyxoviridae, orthomyxoviridae, picornaviridae, and herpesviridae). [41][42][43][44][45][46][47][48][49][50][51][52][53][54][55]…”

Section: Emerging Viral Infections Other Than Covid-19mentioning

confidence: 99%

“…There were only 3 studies examining the association between preexisting hypertension or CVD and other emerging viral infections, with 2 on West Nile virus and 1 on Lassa fever. 42,47,51 Viral Infection or Severity One study found a history of CVD was not associated with West Nile virus infection. In a cross-sectional hospital study in urban Nigeria, having hypertension was not associated with higher odds of having West Nile, but the diagnosis of hypertension relied on self-report.…”

Section: Influence Of Preexisting Hypertension and Cvd On Emerging Vi...mentioning

confidence: 99%

See 1 more Smart Citation

Emerging Viral Infections, Hypertension, and Cardiovascular Disease in Sub-Saharan Africa: A Narrative Review

et al. 2022

View full text Add to dashboard Cite

Background: Sub-Saharan Africa (SSA) has the highest age-adjusted burden of hypertension and cardiovascular disease (CVD). SSA also experiences many viral infections due to unique environmental and societal factors. The purpose of this narrative review is to examine evidence around how hypertension, CVD, and emerging viral infections interact in SSA. Methods: In September 2021, we conducted a search in MEDLINE, Embase, and Scopus, limited to English language studies published since 1990, and found a total of 1169 articles. Forty-seven original studies were included, with 32 on COVID-19 and 15 on other emerging viruses. Results: Seven articles, including those with the largest sample size and most robust study design, found an association between preexisting hypertension or CVD and COVID-19 severity or death. Ten smaller studies found no association, and 17 did not calculate statistics to compare groups. Two studies assessed the impact of COVID-19 on incident CVD, with one finding an increase in stroke admissions. For other emerging viruses, 3 studies did not find an association between preexisting hypertension or CVD on West Nile and Lassa fever mortality. Twelve studies examined other emerging viral infections and incident CVD, with 4 finding no association and 8 not calculating statistics. Conclusions: Growing evidence from COVID-19 suggests viruses, hypertension, and CVD interact on multiple levels in SSA, but research gaps remain especially for other emerging viral infections. SSA can and must play a leading role in the study and control of emerging viral infections, with expansion of research and public health infrastructure to address these interactions.

show abstract

Epidemiological characteristics of Lassa fever cases in Liberia: a retrospective analysis of surveillance data, 2019–2020

Jetoh¹,

Malik²,

Shobayo³

et al. 2022

International Journal of Infectious Diseases

View full text Add to dashboard Cite

A description of Lassa Fever mortality during the 2019 outbreak in Nigeria

Cited by 6 publications

References 0 publications

Combating Lassa Fever in West African Sub-Region: Progress, Challenges, and Future Perspectives

Combating Lassa Fever in West African Sub-Region: Progress, Challenges, and Future Perspectives

Emerging Viral Infections, Hypertension, and Cardiovascular Disease in Sub-Saharan Africa: A Narrative Review

Epidemiological characteristics of Lassa fever cases in Liberia: a retrospective analysis of surveillance data, 2019–2020

Contact Info

Product

Resources

About